Brief: GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx and GenomeDx Testing
20/10/2025 13:10
Oct 20 (Reuters) - GeneDx Holdings Corp WGS.O: GENEDX GRANTED FDA BREAKTHROUGH DEVICE DESIGNATION FOR ITS EXOMEDX™ AND GENOMEDX™ TESTING GENEDX HOLDINGS CORP - DESIGNATION PROVIDES GENEDX EXPEDITED FDA REVIEW PATHWAY Source text: ID:nBw45xs7Ha Further company coverage: WGS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GeneDx Holdings
See all newsBrief: Genedx Launches New Online Offering For Families To Improve Accessibility Of Exome Testing For Children
GeneDx Holdings Corp reports results for the quarter ended June 30 - Earnings Summary
GeneDx Q2 revenue beats analyst estimates
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys
Brief: Genedx Names Mark Gardner President To Lead Its Next Phase Of Scale And Growth